A Study of GRN163L With Paclitaxel and Bevacizumab to Treat Patients With Locally Recurrent Or Metastatic Breast Cancer
- First Posted Date
- 2008-08-11
- Last Posted Date
- 2015-12-24
- Lead Sponsor
- Geron Corporation
- Target Recruit Count
- 24
- Registration Number
- NCT00732056
- Locations
- ๐บ๐ธ
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
๐บ๐ธIngalls Memorial Hospital, Harvey, Illinois, United States
Safety and Dose Study of GRN163L and Velcade to Treat Patients With Refractory or Relapsed Myeloma
- First Posted Date
- 2008-07-18
- Last Posted Date
- 2015-12-24
- Lead Sponsor
- Geron Corporation
- Target Recruit Count
- 40
- Registration Number
- NCT00718601
- Locations
- ๐บ๐ธ
Karmanos Cancer Center, Detroit, Michigan, United States
๐บ๐ธSt. Vincent's Comprehensive Cancer Center, New York City, New York, United States
๐บ๐ธFred Hutchinson Cancer Research Center, Seattle, Washington, United States
Safety and Dose Study of GRN163L Administered to Treat Patients With Refractory or Relapsed Multiple Myeloma
- First Posted Date
- 2008-01-15
- Last Posted Date
- 2015-12-24
- Lead Sponsor
- Geron Corporation
- Target Recruit Count
- 20
- Registration Number
- NCT00594126
- Locations
- ๐บ๐ธ
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland, United States
๐บ๐ธDana Farber Cancer Institute, Boston, Massachusetts, United States
๐บ๐ธRoswell Park Cancer Institute, Buffalo, New York, United States
Study of GRN163L With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Non Small Cell Lung Cancer
- First Posted Date
- 2007-08-02
- Last Posted Date
- 2015-12-24
- Lead Sponsor
- Geron Corporation
- Target Recruit Count
- 27
- Registration Number
- NCT00510445
- Locations
- ๐บ๐ธ
University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States
๐บ๐ธUniversity of Wisconsin, Paul P. Carbone Comprehensive Cancer Center, Madison, Wisconsin, United States
๐บ๐ธUT MD Anderson Cancer Center, Houston, Texas, United States
Safety and Dose Study of GRN163L Administered to Patients With Refractory or Relapsed Solid Tumor Malignancies
- First Posted Date
- 2006-04-05
- Last Posted Date
- 2015-12-24
- Lead Sponsor
- Geron Corporation
- Target Recruit Count
- 85
- Registration Number
- NCT00310895
- Locations
- ๐บ๐ธ
The University of Chicago Medical Center, Chicago, Illinois, United States
๐บ๐ธWayne State University, Karmanos Cancer Center, Detroit, Michigan, United States
Safety and Dose Study of GRN163L to Treat Patients With Chronic Lymphoproliferative Disease(CLD)
- First Posted Date
- 2005-07-27
- Last Posted Date
- 2015-12-24
- Lead Sponsor
- Geron Corporation
- Target Recruit Count
- 48
- Registration Number
- NCT00124189
- Locations
- ๐บ๐ธ
Long Island Jewish Medical Center, New Hyde Park, New York, United States
๐บ๐ธRoswell Park Cancer Center, Buffalo, New York, United States
๐บ๐ธThe Ohio State University James Cancer Hospital, Columbus, Ohio, United States